|
1
|
Law MR, Wald NJ and Rudnicka AR:
Quantifying effect of statins on low density lipoprotein
cholesterol, ischaemic heart disease, and stroke: systematic review
and meta-analysis. BMJ. 326:14232003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mendis S, Puska P and Norrving B: Global
atlas on cardiovascular disease prevention and control. World
Health Organization; Geneva: 2011
|
|
3
|
Brown MS and Goldstein JL: Biomedicine.
Lowering LDL - not only how low, but how long? Science.
311:1721–1723. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mihaylova B, Emberson J, Blackwell L,
Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R and
Baigent C: Cholesterol Treatment Trialists' (CTT) Collaborators:
the effects of lowering LDL cholesterol with statin therapy in
people at low risk of vascular disease: meta-analysis of individual
data from 27 randomised trials. Lancet. 380:581–590. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baigent C, Blackwell L, Emberson J,
Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J,
et al: Cholesterol Treatment Trialists' (CTT) Collaboration:
Efficacy and safety of more intensive lowering of LDL cholesterol:
a meta-analysis of data from 170,000 participants in 26 randomised
trials. Lancet. 376:1670–1681. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reiner Z, Catapano AL, De Backer G, Graham
I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ,
Durrington P, et al: European Association for Cardiovascular
Prevention & Rehabilitation; ESC Committee for Practice
Guidelines (CPG) 2008–2010 and 2010–2012 Committees: ESC/EAS
Guidelines for the management of dyslipidaemias: The Task Force for
the management of dyslipidaemias of the European Society of
Cardiology (ESC) and the European Atherosclerosis Society (EAS).
Eur Heart J. 32:1769–1818. 2011.PubMed/NCBI
|
|
7
|
Koo BK: Statin for the primary prevention
of cardiovascular disease in patients with diabetes mellitus.
Diabetes Metab J. 38:32–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Joy TR: Novel therapeutic agents for
lowering low density lipoprotein cholesterol. Pharmacol Ther.
135:31–43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pijlman AH, Huijgen R, Verhagen SN, Imholz
BP, Liem AH, Kastelein JJ, Abbink EJ, Stalenhoef AF and Visseren
FL: Evaluation of cholesterol lowering treatment of patients with
familial hypercholesterolemia: a large cross-sectional study in The
Netherlands. Atherosclerosis. 209:189–194. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Barter PJ, Caulfield M, Eriksson M, Grundy
SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC,
Waters DD, et al: ILLUMINATE Investigators: Effects of torcetrapib
in patients at high risk for coronary events. N Engl J Med.
357:2109–2122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Landray MJ, Haynes R, Hopewell JC, Parish
S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, et
al: HPS2-THRIVE Collaborative Group: Effects of extended-release
niacin with laropiprant in high-risk patients. N Engl J Med.
371:203–212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cannon CP, Blazing MA, Giugliano RP,
McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO,
Jukema JW, et al: IMPROVE-IT Investigators: Ezetimibe added to
statin therapy after acute coronary syndromes. N Engl J Med.
372:2387–2397. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ginsberg HN, Elam MB, Lovato LC, Crouse JR
III, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC,
Probstfield J, et al: ACCORD Study Group: Effects of combination
lipid therapy in type 2 diabetes mellitus. N Engl J Med.
362:1563–1574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stone NJ, Robinson JG, Lichtenstein AH,
Merz CN Bairey, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D,
Lloyd-Jones DM, et al: American College of Cardiology/American
Heart Association Task Force on Practice Guidelines: 2013 ACC/AHA
guideline on the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular risk in adults: a report of the
American College of Cardiology/American Heart Association Task
Force on Practice Guidelines. J Am Coll Cardiol. 63:2889–2934.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Seidah NG, Benjannet S, Wickham L,
Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A and Chretien
M: The secretory proprotein convertase neural apoptosis-regulated
convertase 1 (NARC-1): liver regeneration and neuronal
differentiation. Proc Natl Acad Sci USA. 100:928–933. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Abifadel M, Varret M, Rabès JP, Allard D,
Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich
D, et al: Mutations in PCSK9 cause autosomal dominant
hypercholesterolemia. Nat Genet. 34:154–156. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seidah NG, Sadr MS, Chrétien M and Mbikay
M: The multifaceted proprotein convertases: their unique,
redundant, complementary, and opposite functions. J Biol Chem.
288:21473–21481. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seidah NG, Awan Z, Chrétien M and Mbikay
M: PCSK9: a key modulator of cardiovascular health. Circ Res.
114:1022–1036. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Artenstein AW and Opal SM: Proprotein
convertases in health and disease. N Engl J Med. 365:2507–2518.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Seidah NG and Prat A: The biology and
therapeutic targeting of the proprotein convertases. Nat Rev Drug
Discov. 11:367–383. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D
and Park SW: Sterol-dependent regulation of proprotein convertase
subtilisin/kexin type 9 expression by sterol-regulatory element
binding protein-2. J Lipid Res. 49:399–409. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Benjannet S, Rhainds D, Essalmani R, Mayne
J, Wickham L, Jin W, Asselin MC, Hamelin J, Varret M, Allard D, et
al: NARC-1/PCSK9 and its natural mutants: Zymogen cleavage and
effects on the low density lipoprotein (LDL) receptor and LDL
cholesterol. J Biol Chem. 279:48865–48875. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cunningham D, Danley DE, Geoghegan KF,
Griffor MC, Hawkins JL, Subashi TA, Varghese AH, Ammirati MJ, Culp
JS, Hoth LR, et al: Structural and biophysical studies of PCSK9 and
its mutants linked to familial hypercholesterolemia. Nat Struct Mol
Biol. 14:413–419. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Denis M, Marcinkiewicz J, Zaid A, Gauthier
D, Poirier S, Lazure C, Seidah NG and Prat A: Gene inactivation of
proprotein convertase subtilisin/kexin type 9 reduces
atherosclerosis in mice. Circulation. 125:894–901. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lo Surdo P, Bottomley MJ, Calzetta A,
Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A and
Carfí A: Mechanistic implications for LDL receptor degradation from
the PCSK9/LDLR structure at neutral pH. EMBO Rep. 12:1300–1305.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Akram ON, Bernier A, Petrides F, Wong G
and Lambert G: Beyond LDL cholesterol, a new role for PCSK9.
Arterioscler Thromb Vasc Biol. 30:1279–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Le May C, Kourimate S, Langhi C,
Chétiveaux M, Jarry A, Comera C, Collet X, Kuipers F, Krempf M,
Cariou B, et al: Proprotein convertase subtilisin kexin type 9 null
mice are protected from postprandial triglyceridemia. Arterioscler
Thromb Vasc Biol. 29:684–690. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang S, Henry L, Ho YK, Pownall HJ and
Rudenko G: Mechanism of LDL binding and release probed by
structure-based mutagenesis of the LDL receptor. J Lipid Res.
51:297–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nassoury N, Blasiole DA, Oler A Tebon,
Benjannet S, Hamelin J, Poupon V, McPherson PS, Attie AD, Prat A
and Seidah NG: The cellular trafficking of the secretory proprotein
convertase PCSK9 and its dependence on the LDLR. Traffic.
8:718–732. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cameron J, Holla OL, Ranheim T, Kulseth
MA, Berge KE and Leren TP: Effect of mutations in the PCSK9 gene on
the cell surface LDL receptors. Hum Mol Genet. 15:1551–1558. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Saavedra YG, Day R and Seidah NG: The M2
module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed
for the extracellular low-density lipoprotein receptor (LDLR)
degradation pathway. J Biol Chem. 287:43492–43501. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tveten K, Holla OL, Cameron J, Strøm TB,
Berge KE, Laerdahl JK and Leren TP: Interaction between the
ligand-binding domain of the LDL receptor and the C-terminal domain
of PCSK9 is required for PCSK9 to remain bound to the LDL receptor
during endosomal acidification. Hum Mol Genet. 21:1402–1409. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
DeVay RM, Shelton DL and Liang H:
Characterization of proprotein convertase subtilisin/kexin type 9
(PCSK9) trafficking reveals a novel lysosomal targeting mechanism
via amyloid precursor-like protein 2 (APLP2). J Biol Chem.
288:10805–10818. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tavori H, Fan D, Blakemore JL, Yancey PG,
Ding L, Linton MF and Fazio S: Serum proprotein convertase
subtilisin/kexin type 9 and cell surface low-density lipoprotein
receptor: Evidence for a reciprocal regulation. Circulation.
127:2403–2413. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Raal F, Scott R, Somaratne R, Bridges I,
Li G, Wasserman SM and Stein EA: Low-density lipoprotein
cholesterol-lowering effects of AMG 145, a monoclonal antibody to
proprotein convertase subtilisin/kexin type 9 serine protease in
patients with heterozygous familial hypercholesterolemia: The
Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial
Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Circulation. 126:2408–2417. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Leren TP: Mutations in the PCSK9 gene in
Norwegian subjects with autosomal dominant hypercholesterolemia.
Clin Genet. 65:419–422. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Stefanutti C, Morozzi C and Di Giacomo S:
New clinical perspectives of hypolipidemic drug therapy in severe
hypercholesterolemia. Curr Med Chem. 19:4861–4868. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Allard D, Amsellem S, Abifadel M, Trillard
M, Devillers M, Luc G, Krempf M, Reznik Y, Girardet JP, Fredenrich
A, et al: Novel mutations of the PCSK9 gene cause variable
phenotype of autosomal dominant hypercholesterolemia. Hum Mutat.
26:4972005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cohen JC, Boerwinkle E, Mosley TH Jr and
Hobbs HH: Sequence variations in PCSK9, low LDL, and protection
against coronary heart disease. N Engl J Med. 354:1264–1272. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dewpura T, Raymond A, Hamelin J, Seidah
NG, Mbikay M, Chrétien M and Mayne J: PCSK9 is phosphorylated by a
Golgi casein kinase-like kinase ex vivo and circulates as a
phosphoprotein in humans. FEBS J. 275:3480–3493. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Benn M, Nordestgaard BG, Grande P, Schnohr
P and Tybjaerg-Hansen A: PCSK9 R46L, low-density lipoprotein
cholesterol levels, and risk of ischemic heart disease: 3
independent studies and meta-analyses. J Am Coll Cardiol.
55:2833–2842. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kathiresan S: Myocardial Infarction
Genetics Consortium: A PCSK9 missense variant associated with a
reduced risk of early-onset myocardial infarction. N Engl J Med.
358:2299–2300. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Marais AD, Kim JB, Wasserman SM and
Lambert G: PCSK9 inhibition in LDL cholesterol reduction: Genetics
and therapeutic implications of very low plasma lipoprotein levels.
Pharmacol Ther. 145:58–66. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch
L, Grishin NV, Horton JD, Cohen JC and Hobbs HH: Molecular
characterization of loss-of-function mutations in PCSK9 and
identification of a compound heterozygote. Am J Hum Genet.
79:514–523. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mayne J, Dewpura T, Raymond A, Bernier L,
Cousins M, Ooi TC, Davignon J, Seidah NG, Mbikay M and Chrétien M:
Novel loss-of-function PCSK9 variant is associated with low plasma
LDL cholesterol in a French-Canadian family and with impaired
processing and secretion in cell culture. Clin Chem. 57:1415–1423.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Druce I, Abujrad H and Ooi TC: PCSK9 and
triglyceride-rich lipoprotein metabolism. J Biomed Res.
29:292015.
|
|
47
|
Giugliano RP, Desai NR, Kohli P, Rogers
WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald
ST, et al: LAPLACE-TIMI 57 Investigators: Efficacy, safety, and
tolerability of a monoclonal antibody to proprotein convertase
subtilisin/kexin type 9 in combination with a statin in patients
with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised,
placebo-controlled, dose-ranging, phase 2 study. Lancet.
380:2007–2017. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Raal FJ, Stein EA, Dufour R, Turner T,
Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D,
et al: RUTHERFORD-2 Investigators: PCSK9 inhibition with evolocumab
(AMG 145) in heterozygous familial hypercholesterolaemia
(RUTHERFORD-2): a randomised, double-blind, placebo-controlled
trial. Lancet. 385:331–340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Latimer J, Batty JA, Neely RD and Kunadian
V: PCSK9 inhibitors in the prevention of cardiovascular disease. J
Thromb Thrombolysis. Apr 19–2016.(Epub ahead of print). View Article : Google Scholar
|
|
50
|
Cicero AF, Tartagni E and Ertek S: Safety
and tolerability of injectable lipid-lowering drugs: a review of
available clinical data. Expert Opin Drug Saf. 13:1023–1030. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Roth EM, Taskinen MR, Ginsberg HN,
Kastelein JJ, Colhoun HM, Robinson JG, Merlet L, Pordy R and
Baccara-Dinet MT: Monotherapy with the PCSK9 inhibitor alirocumab
versus ezetimibe in patients with hypercholesterolemia: results of
a 24 week, double-blind, randomized phase 3 trial. Int J Cardiol.
176:55–61. 2014. View Article : Google Scholar : PubMed/NCBI
|
